Many providers have begun to switch patients from tirzepatide to semaglutide or, when they can afford it, to the brand-name drug
The half-life ( t ) of oral semaglutide was shown to be similar to that of s.c
Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Professor Heidi Crane of the University of Washington in Seattle presented further evidence at CROI, showing that semaglutide led to significant weight loss among people with HIV (an average of 6.5kg, or about 6% of body weight) over one year
and Mounjaros active ingredient, tirzepatide, was approved for weight loss in the form of Zepbound in 2023